Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 4/20 | 0.39 |
| ▸ | DRD2 | P14416 | 1/20 | 0.36 |
| ▸ | DRD3 | P35462 | 1/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.36 |
| ▸ | HTR7 | P34969 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23249586 | 0.82 | HTR1A (0.39) | HTR1ADRD2DRD3HTR7 | |
| SCHEMBL23249571 | 0.77 | SLC6A2 (0.32) | HTR1ASLC6A2SLC6A4SLC6A3 | |
| SCHEMBL23261646 | 0.77 | DRD2 (0.36) | HTR1ADRD2DRD3SLC6A2SLC6A4 | |
| SCHEMBL6356879 | 0.73 | HTR1A (0.68) | HTR1ADRD2DRD3SLC6A2SLC6A4 | |
| SCHEMBL31635823 | 0.73 | HTR1A (0.68) | HTR1ADRD2DRD3SLC6A2SLC6A4 | |
| SCHEMBL23249314 | 0.73 | HTR1A (0.68) | HTR1ADRD2DRD3SLC6A2SLC6A4 | |
| SCHEMBL23261784 | 0.73 | HTR1A (0.68) | HTR1ADRD2DRD3SLC6A2SLC6A4 | |
| SCHEMBL23249297 | 0.72 | HTR1A (0.44) | HTR1ADRD2DRD3SLC6A2SLC6A4 | |
| SCHEMBL23248775 | 0.68 | HTR1A (0.45) | HTR1ADRD2DRD3SLC6A2SLC6A4 | |
| SCHEMBL31649795 | 0.68 | HTR1A (0.45) | HTR1ADRD2DRD3SLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230295106-A1 | ERGOLINE-LIKE COMPOUNDS FOR PROMOTING NEURAL PLASTICITY | DELIX THERAPEUTICS, INC. | 2023-09-21 | — | — | US | disclosed |
| US-20230295106-A1 | ERGOLINE-LIKE COMPOUNDS FOR PROMOTING NEURAL PLASTICITY | DELIX THERAPEUTICS, INC. | 2023-09-21 | — | — | US | disclosed |
| US-20230295106-A1 | ERGOLINE-LIKE COMPOUNDS FOR PROMOTING NEURAL PLASTICITY | DELIX THERAPEUTICS, INC. | 2023-09-21 | — | — | US | disclosed |
| WO-2021076572-A1 | ERGOLINE-LIKE COMPOUNDS FOR PROMOTING NEURAL PLASTICITY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-04-22 | — | — | WO | disclosed |
| WO-2021076572-A1 | ERGOLINE-LIKE COMPOUNDS FOR PROMOTING NEURAL PLASTICITY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-04-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230295106-A1 | ERGOLINE-LIKE COMPOUNDS FOR PROMOTING NEURAL PLASTICITY | GRIN1, GRIN2A, GRIN3B | HTR1A 746/4885DRD2 184/4885DRD3 375/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.